Related Experiment Video
Updated: Jun 23, 2025
Flow Cytometric Analysis of Extracellular Vesicles from Cell-conditioned Media
Published on: February 12, 2019
Evolving Strategies for Extracellular Vesicles as Future Cardiac Therapeutics: From Macro- to Nano-Applications
Laura Guerricchio1, Lucio Barile2,3, Sveva Bollini1,4
1Biology Unit, Department of Experimental Medicine (DIMES), University of Genova, 16132 Genova, Italy.
Insights
Extracellular vesicles (EVs) from human progenitor cells show promise for treating cardiovascular disease and heart failure. Research focuses on optimizing EV delivery and targeting for effective cardiac repair and regenerative medicine.
Area of Science:
- Regenerative Medicine
- Cardiovascular Research
- Cell Biology
Background:
- Cardiovascular disease is a leading cause of death globally, exacerbated by an aging population.
- Heart failure, resulting from myocardial infarction or cardiomyopathy, lacks effective repair strategies beyond transplantation.
- Extracellular vesicles (EVs) are emerging as potential therapeutic agents for cardiac regenerative medicine.
Purpose of the Study:
- To review the therapeutic potential of human progenitor cell-derived EVs for cardiovascular diseases.
- To highlight strategies for improving myocardial targeting and administration of EVs.
- To discuss the role of EVs in cardiac regenerative medicine and future clinical translation.
Main Methods:
- Review of preclinical studies on the cardioprotective and cardioactive effects of progenitor cell-derived EVs.
- Analysis of current research on EV delivery strategies and cardiac targeting.
- Discussion of challenges and advancements in EV-based paracrine therapy.
Main Results:
- Human progenitor cell-derived EVs exhibit significant cardioprotective and cardioactive potential in preclinical models.
- EVs are promising candidates for paracrine therapy in cardiovascular disease.
- Optimizing EV delivery and cardiac targeting remains crucial for clinical success.
Conclusions:
- EVs derived from human progenitor cells offer a viable therapeutic avenue for cardiovascular diseases.
- Further research into optimized delivery and targeting strategies is essential for clinical translation.
- EV-based therapies hold significant promise for advancing cardiac regenerative medicine.
Abstract:
Cardiovascular disease represents the foremost cause of mortality and morbidity worldwide, with a steadily increasing incidence due to the growth of the ageing population. Cardiac dysfunction leading to heart failure may arise from acute myocardial infarction (MI) as well as inflammatory- and cancer-related chronic cardiomyopathy. Despite pharmacological progress, effective cardiac repair represents an unmet clinical need, with heart transplantation being the only option for end-stage heart failure. The functional profiling of the biological activity of extracellular vesicles (EVs) has recently attracted increasing interest in the field of translational research for cardiac regenerative medicine. The cardioprotective and cardioactive potential of human progenitor stem/cell-derived EVs has been reported in several preclinical studies, and EVs have been suggested as promising paracrine therapy candidates for future clinical translation. Nevertheless, some compelling aspects must be properly addressed, including optimizing delivery strategies to meet patient needs and enhancing targeting specificity to the cardiac tissue. Therefore, in this review, we will discuss the most relevant aspects of the therapeutic potential of EVs released by human progenitors for cardiovascular disease, with a specific focus on the strategies that have been recently implemented to improve myocardial targeting and administration routes.
